Six collaborations driving drug discovery innovation
Drug Discovery World
JANUARY 15, 2024
For an additional $28 million, Lantheus has obtained an option to exclusively license Perspective’s neuroendocrine tumours treatment Pb212-VMT-⍺-NET, or to co-develop certain early stage therapeutic candidates targeting prostate cancer. of Perspective’s shares for up to $33 million.
Let's personalize your content